nantradol (levonantradol)

cannabinoid-related analgetic with greater potency than morphine in some tests; 4 stereoisomers are mentioned in the literature: (+)-2'(S),6(R),6a(S),9(S)10a(S) [CP-53,870-1]; (-)-2'(R),6(S),6a(R),9(R)10a(R) [CP-50,556-1]; (+)-2'(R),6(R),6a(S),9(S),10a(S); (-)-2'(S),6(S),6a(R),9(R)10a(R); RN given is from CA 1977-79 Index Guide; structure in first source; use STEREOISOMERS if levonantradol is used

Also Known As:

levonantradol; nantradol hydrochloride; nantradol hydrochloride (6S-(3(S*), 6alpha,6aalpha,9alpha,10abeta))-isomer; nantradol hydrochloride, (3(R*),6alpha,6aalpha,9alpha,10abeta)-(+)-isomer; nantradol, ((3(R*),6alpha,6aalpha,9alpha,10abeta)-(+-))-isomer; nantradol, ((3(S*),6alpha,6aalpha,9alpha,10abeta)-(+-))-isomer; nantradol, (6R-(3(S*),6alpha,6aalpha,9alpha,10abeta))-isomer; nantradol, (6S-(3(S*),6alpha,6aalpha,9alpha,10abeta))-isomer; 1,9-phenanthridinediol, 5,6,6a,7,8,9,10,10a-octahydro-6-methyl-3-(1-methyl-4-phenylbutoxy)-, 1-acetate, (6 alpha,6a alpha,9 alpha,10a beta)-(+-)-

Networked: 33 relevant articles (5 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Phenanthridines: 3
      - nantradol: 33

Experts

1.	Howlett, A C: 2 articles (06/2001 - 11/2000)
2.	Meschler, J P: 2 articles (06/2001 - 11/2000)
3.	Madras, B K: 1 article (06/2001)
4.	Darmani, N A: 1 article (02/2001)
5.	Conley, T J: 1 article (11/2000)

Related Diseases

1.	Vomiting 12/01/1985 - "Phase 1 trial of levonantradol in chemotherapy-induced emesis." 08/01/1981 - "Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations." 08/01/1981 - "It is suggested that a combination of oral and parenteral levonantradol may prove to be a very effective program to relieve the otherwise disabling problems of persistent nausea and vomiting." 08/01/1981 - "Levonantradol for chemotherapy-induced emesis: phase I-II oral administration." 07/15/1983 - "Levonantradol for the treatment of chemotherapy-induced nausea and vomiting."
2.	Nausea 08/01/1981 - "It is suggested that a combination of oral and parenteral levonantradol may prove to be a very effective program to relieve the otherwise disabling problems of persistent nausea and vomiting." 07/15/1983 - "Levonantradol for the treatment of chemotherapy-induced nausea and vomiting." 08/20/1982 - "[Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author's transl) clinical studies]." 08/01/1981 - "Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting." 01/01/1985 - "Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting."
3.	Neoplasms (Cancer) 01/01/1983 - "A dose-ranging study with oral levonantradol was performed in 20 cancer patients. " 08/01/1981 - "These data support the use of levonantradol in conjunction with chemotherapy in cancer patients." 08/01/1981 - "The effects of levonantradol hydrochloride on tumor growth and therapy." 12/01/1982 - "Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics." 08/01/1981 - "Likewise, the increased survival obtained in both tumor systems with cyclophosphamide was not altered by concurrent administration of levonantradol hydrochloride. "
4.	Seizures (Absence Seizure) 08/01/1981 - "However, levonantradol did increase the latency of appearance of fully kindled seizures at the 400 micrograms/kg dose. " 08/01/1981 - "Levonantradol administered in doses of 100 to 400 micrograms/kg did not block any components of the motor seizure. " 08/01/1981 - "Levonantradol, at doses of 0.32 and 3.2 mg/kg subcutaneously, which did not block the convulsant effect of pentylenetetrazol, enhanced both the potency and efficacy of diazepam in elevating the absolute threshold of pentylenetetrazol for eliciting clonic seizures. " 08/01/1981 - "Although the mechanism underlying this potentiation of the antiepileptic effects of valproic acid and diazepam remains unknown, levonantradol may have potential as adjunctive therapy in the treatment of complex partial seizures." 08/01/1981 - "The anticonvulsant effects of the cannabinoid derivative levonantradol and its ability to potentiate the anticonvulsant effects of diazepam and valproic acid were studied in rats with previously established amygdala-kindled seizures. "
5.	Shock 01/01/1985 - "These results extend observations for the acute effects of l-nantradol and clonidine to operant responding under a schedule of continuous shock avoidance. " 07/01/1985 - "Marked tolerance developed for the shock-increasing effects of morphine (3.0 mg/kg) and l-nantradol (0.3 mg/kg) within 10 to 15 sessions, but only partial tolerance developed for shock-increasing effects of clonidine (0.3 mg/kg) after up to 35 sessions. " 07/01/1985 - "Morphine and l-nantradol resulted in markedly higher shock intensities only at doses that severely disrupted responding, whereas clonidine resulted in higher shock intensities over a broader dose range without disrupting responding. " 01/01/1983 - "Nantradol (0.1-0.3 mg/kg), levonantradol (0.03-0.1 mg/kg), or N-methyl levonantradol (0.01-0.03 mg/kg) increased the level at which shock was maintained, but did not change rates of responding. " 01/01/1983 - "Electric shock titration in squirrel monkeys following administration of nantradol, levonantradol, or N-methyl levonantradol."

Related Drugs and Biologics

1.	Antiemetics
2.	Dronabinol (THC)
3.	Diazepam (Valium)
4.	Pentylenetetrazole (Metrazol)
5.	Metoclopramide (Reglan)
6.	Convulsants
7.	Cannabinoids
8.	Cytostatic Agents
9.	Prochlorperazine (Compazine)
10.	Chlorpromazine (Thorazine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Intramuscular Injections
5.	Injections